Joseph Oliveto Sells 133,054 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 133,054 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $308,685.28. Following the completion of the transaction, the chief executive officer directly owned 450,667 shares of the company’s stock, valued at approximately $1,045,547.44. This represents a 22.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total value of $1,125.00.

Milestone Pharmaceuticals Stock Down 2.6%

Shares of MIST opened at $1.89 on Friday. The firm has a market capitalization of $160.97 million, a price-to-earnings ratio of -2.30 and a beta of 0.44. Milestone Pharmaceuticals Inc. has a 52 week low of $0.63 and a 52 week high of $3.06. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The business’s fifty day moving average price is $2.23 and its two-hundred day moving average price is $1.96.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.05. On average, analysts predict that Milestone Pharmaceuticals Inc. will post -0.62 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Zacks Research raised Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Finally, TD Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIST. October Effect Ltd acquired a new stake in shares of Milestone Pharmaceuticals during the fourth quarter worth about $105,000. SG Americas Securities LLC bought a new position in Milestone Pharmaceuticals in the fourth quarter valued at approximately $197,000. Bay Rivers Group boosted its holdings in shares of Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock valued at $58,000 after buying an additional 12,170 shares during the period. Millennium Management LLC bought a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $803,000. Finally, Boxer Capital Management LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth $1,333,000. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals News Roundup

Here are the key news stories impacting Milestone Pharmaceuticals this week:

• Positive Sentiment: Milestone announced U.S. pharmacy availability of its CARDAMYST nasal spray — a commercial launch that begins the company’s transition from development to product revenue and increases commercial visibility. Read More.
• Positive Sentiment: Zacks Research upgraded MIST from “Hold” to “Strong Buy,” which can attract short‑term buyers and momentum flows into a thinly traded microcap. Read More.
• Neutral Sentiment: Technical/trading context is mixed: shares sit below the 50‑day moving average and current volume is below the stock’s average, which may limit a sustained rally despite the launch and upgrade.
• Negative Sentiment: CEO Joseph Oliveto executed large sales (133,054 shares on Dec. 15 at ~$2.32 and 34,523 shares on Jan. 26 at ~$1.93). Material insider reductions by the CEO often trigger investor concern about insider conviction and can add selling pressure. Read More.
• Negative Sentiment: Other senior insiders (COO Jeffrey Nelson, and executives David Bharucha and Lorenz Muller) also sold large blocks on Dec. 15 and Jan. 26, representing double‑digit percentage cuts to their stakes—a clustered pattern that intensifies negative sentiment and helps explain downward pressure on the share price. Read More. Read More. Read More.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.